| 0 (0%) | 04-23 10:30 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 264.2 | 1-year : | 270.81 |
| Resists | First : | 226.2 | Second : | 231.86 |
| Pivot price | 222.14 |
|||
| Supports | First : | 217.05 | Second : | 180.58 |
| MAs | MA(5) : | 218.99 |
MA(20) : | 223.92 |
| MA(100) : | 210.09  |
MA(250) : | 190.14 |
|
| MACD | MACD : | -1.4 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 13.4 |
D(3) : | 12.5 |
| RSI | RSI(14): 41.1 |
|||
| 52-week | High : | 231.86 | Low : | 156.72 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ECL ] has closed above bottom band by 27.3%. Bollinger Bands are 12.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 220.25 - 221.58 | 221.58 - 222.86 |
| Low: | 214.1 - 215.68 | 215.68 - 217.19 |
| Close: | 216.9 - 219.22 | 219.22 - 221.44 |
Tue, 23 Apr 2024
FDA Rejects Abeona’s Epidermolysis Bullosa Cell Therapy, Asks for CMC Data - BioSpace
Mon, 22 Apr 2024
Curocell applies for expedited approval of CAR-T therapy - KBR
Mon, 22 Apr 2024
FDA requests more info for Abeona pz-cel market application (NASDAQ:ABEO) - Seeking Alpha
Mon, 22 Apr 2024
Abeona Therapeutics Provides Regulatory Update on Pz-cel - GlobeNewswire
Mon, 22 Apr 2024
Cilta-Cel Allows for Treatment-Free Period in Early R/R Multiple Myeloma - OncLive
Mon, 15 Apr 2024
Environmental Commission Gets Focuses on Exploring Hawthorne at this Year's Cel-Earth-Bration - TAPinto.net
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 286 (M) |
| Shares Float | 254 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 89.8 (%) |
| Shares Short | 2,030 (K) |
| Shares Short P.Month | 1,930 (K) |
| EPS | 4.8 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 23.45 |
| Profit Margin | 8.9 % |
| Operating Margin | 14.7 % |
| Return on Assets (ttm) | 6.3 % |
| Return on Equity (ttm) | 18.1 % |
| Qtrly Rev. Growth | 17.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 53.58 |
| EBITDA (p.s.) | 10.87 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 2,410 (M) |
| Levered Free Cash Flow | 1,550 (M) |
| PE Ratio | 45.63 |
| PEG Ratio | 2.2 |
| Price to Book value | 9.33 |
| Price to Sales | 4.08 |
| Price to Cash Flow | 25.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|